Proactive Investors - Run By Investors For Investors

Tissue Regenix boss to take leave of absence to undergo medical treatment

Steve Couldwell will step aside in January in order to undergo treatment for an unspecified medical condition, although he should be back by March
steve couldwell
Chairman John Samuel will take over the reins in Couldwell’s absence

Steve Couldwell, the chief executive of regenerative medicines specialist Tissue Regenix Group PLC (LON:TRX), is taking a temporary leave of absence early next year in order to undergo medical treatment.

Couldwell will temporarily step aside in January and is expected to be out of action until March.

READ: TRX's CellRight subsidiary inks European distribution deal

In his absence, chairman John Samuel will become executive chairman, while chief financial officer Gareth Jones will take on the role of chief operating officer.

Samuel and Jones will hold those positions on an interim basis.

“Steve has done an excellent job of establishing a sound business strategy and delivering positive sales momentum,” said chairman Samuel.

“We are confident we will continue to execute against this strategy and on behalf of the Board and everyone at Tissue Regenix, I wish Steve a full and speedy recovery.”

As for current trading, a brief line at the end of the stock exchange announcement confirmed that the company remains on track to meet full-year expectations.

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
pills
November 07 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use